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Abstract
Purpose The estrogen (ER), progesterone (PR), and HER2 status are essential in guiding treatment decisions in breast can-
cer patients. In daily life, the ER/PR/HER2 status is expected to be commonly tested twice, i.e., at diagnosis using material 
from tumor needle biopsies, and after tumor resection using full tumor tissue material. This study explored the discordance 
of ER/PR/HER2 between tumor needle biopsies and full tumor resection material using real-world patient-level data from 
Dutch breast cancer patients.
Methods Pathology reports of 11,054 breast cancer patients were derived from PALGA (Dutch Pathology Registry). Dis-
cordance was calculated for multiple combinations of the ER/PR/HER2 receptor status. The influence of patient and tumor 
characteristics on the probability of having discordant test results was analyzed using multiple logistic regression models 
(separately for ER, PR and HER2).
Results For 1279 patients (14.4%), at least one of the receptors (ER/PR/HER2) was determined on both biopsy and tumor 
tissue material. The majority had concordant test results for ER (n = 916; 94.8%), PR (n = 1170; 86.7%), and HER2 (n = 881; 
98.1%). Patients having an ER- and HER2-positive but PR-negative biopsy classification, BR grade III, and < 10% tumor 
tissue remaining after neoadjuvant therapy (NAT) have the highest probability of ER discordant test results (OR 4.991; 
p = 83.31%). The probability of discordance in PR is based on different sets of patient and tumor characteristics. Potential 
cost savings from omitting multiple tests if concordance can be perfectly predicted can be up to €205,000 yearly.
Conclusions Double testing of ER/PR/HER2 is less common than expected. Discordance in ER/PR/HER2 test results 
between tumor needle biopsy taken at the time of diagnosis and tumor resection material is very low, especially in patients 
not receiving any form of neoadjuvant therapy. These results imply that a substantial number of tests can potentially be 
omitted in specific subgroups of breast cancer patients.
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Background
Breast cancer is the most frequently diagnosed form of can-
cer among women with yearly incidence rates of almost 
15,000 women in the Netherlands [1]. Of all women diag-
nosed with breast cancer, 90% presents with primary breast 
cancer without distant metastases [2]. In patients with pri-
mary breast cancer, the risk of relapse is determined based 
on factors such as tumor size, tumor grade, and lymph node 
involvement, and if considered high, patients are candidates 
for peri-operative systemic treatment aiming to reduce the 
relapse risk. The type of systemic treatment prescribed is 
currently mainly dependent on the determination of the ER, 
PR and HER2 status of the tumor [3]. The ER/PR/HER2 
status can be determined on tumor needle biopsy material or 
on tumor resection specimen using immunohistochemistry 
(IHC). For the HER2 status, additional in situ hybridization 
(ISH) test is recommended to confirm the HER2 status in 
case IHC results are equivocal [4, 5].
In daily life, the ER/PR/HER2 status is determined mul-
tiple times in many breast cancer patients: first on specimen 
derived from a needle biopsy taken for initial diagnosis, and 
second on the whole tumor specimen obtained by tumor 
resection [4]. Usually, the receptor status results of the tumor 
needle biopsy and the tumor resection are expected to be 
concordant. In patients not receiving any form of neoadju-
vant therapy (NAT) between taking the needle biopsy and 
resection, small series indeed strongly suggest that the con-
cordance between both measurements (biopsy and resec-
tion) is relatively high (range 90.8–97.5%) [6, 7]. However, 
discordance in test results might arise since tumor char-
acteristics can change over time, in particular in patients 
treated with NAT, or because of sampling or analytical 
errors [8–10].
Given the importance of assessing the ER/PR/HER2 
status for treatment decision making, it is essential to get 
more insight into the factors that may underlie discordant 
test results. Apart from consequences for treatment decision 
making, this is also important to improve the cost-effective-
ness of the diagnostic pathway. For those patients in whom it 
is highly unlikely that the second test would yield a discord-
ant test result or a change in clinical management, one of 
the ER/PR/HER2 determinations can potentially be omitted. 
Although the costs of the ER/PR/HER2 tests are relatively 
low, around €100 for an IHC and between €300 and 400 for 
an ISH [11, 12], the cumulative costs of the use of such tests 
can still be high given the large number of patients yearly 
diagnosed with breast cancer.
Several studies have reported on the discordance in ER/
PR/HER2 between tumor needle biopsies and tumor resec-
tion. However, most (recent) studies reported on relatively 
small sample sizes in total and small subgroups of breast 
cancer patients, or included only patients diagnosed at a sin-
gle hospital [7, 13–15]. In the study presented here, we have 
evaluated the discordance in ER/PR/HER2 between tumor 
needle biopsy and tumor resection material in the majority 
of invasive breast cancer patients diagnosed in 2016 and 
2017 in the Netherlands. In addition, the influences of sev-
eral tumor and patient characteristics on the probability of 
discordance in either of the receptors were addressed. Fur-
thermore, potential cost savings due to eliminating over test-
ing in patients with concordant test results were estimated.
Methods
Data sources and description
Data on the ER/PR/HER2 status of invasive breast cancer 
patients were requested from the Dutch Pathology Regis-
try (PALGA), which archives all pathology reports [16]. 
Since 2009, reporting modules are available for creating 
those pathological reports. Within these reports, informa-
tion on patient, tumor, and test characteristics is captured 
in numerous variables instead of in free text fields, which 
improves the possibility of analyzing high numbers of 
reports simultaneously.
Pathology reports of invasive breast cancer patients diag-
nosed between January 12, 2016 and January 1, 2018 were 
extracted from PALGA, as on January 12, 2016 a new syn-
optic reporting module for breast cancer biopsies became 
available that enabled saving more data in a standardized 
way.
Performing more than two tests, thereby creating addi-
tional excerpt records, can have multiple underlying reasons 
which are not always well documented within the pathology 
reports. Therefore, patients having more than two excerpt 
records were removed from further analysis. Discordance, by 
definition, can only exist between multiple measurements. 
Consequently, patients for which only one excerpt record 
was available were also removed from further analysis.
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Discordance in test results
For each excerpt for which the ER and PR status were tested, 
the percentage of tumor cells that stained positive for ER 
and PR and the final classification of the excerpt (positive 
or negative) were registered. According to the Dutch breast 
cancer guideline [4], excerpts with 10% or more cells stained 
positive for ER or PR are classified as being positive. ER 
or PR classifications that deviate from this protocol, i.e., 
excerpts that had less than 10% of cells staining positive for 
ER or PR that were classified as being positive were reclas-
sified according to this 10% threshold.
Tumor needle biopsies will be referred to as biopsies in 
this study, whereas material derived from surgically removed 
tumor tissue will be referred to as the tumor resections. Test 
results between the biopsy and tumor resection were consid-
ered discordant, when the final corrected classification per 
marker, i.e., positive or negative, was different between both 
excerpts. Discordance was calculated for ER, PR, and HER2 
separately, and for ER and PR combined.
Logistic regression analyses
To estimate whether discordance was more likely to occur in 
particular subgroups of patients, three independent logistic 
regression analyses were performed for ER, PR, and HER2. 
These analyses were performed using the glm function from 
the stats package (version 3.5.1) in R (version 3.5.1). Dis-
cordance in either of the receptors was categorized as a bino-
mial variable and was assigned to be the dependent variable, 
whereas the type of NAT (i.e., hormonal–chemotherapy, or 
no neoadjuvant therapy), response to therapy, tumor sub-
type, Bloom Richardson (BR) grade, TNM stage, ER biopsy 
classification, percentage of cells positive for ER on biopsy 
material, PR biopsy classification, percentage of cells posi-
tive for PR on biopsy material, HER2 biopsy classification, 
HER2 IHC result on biopsy material, and HER2 ISH result 
on biopsy material were assigned as independent variables in 
the initial model.
In each of the three analyses, a subset of the data was 
created which contained records of those patients for whom 
the particular receptor under investigation was tested twice. 
The logistic regression models were evaluated using the 
Akaike Information Criterion (AIC) in a stepwise algorithm 
in which both backward and forward selection of variables 
was combined. The stepwise approach was performed using 
the step function from the stats package (version 3.5.1) in R 
(version 3.5.1) and was started with a null model, in which 
no variables were manually added to the initial model. The 
approach was continued with additional steps in which vari-
ables were either added forwards or eliminated backwards in 
each step. The model that was derived when either eliminat-
ing or adding a particular variable to the model did not result 
in a lower AIC of the model was considered to be the model 
with the best performance.
Before running the logistic regression analyses and to 
overcome implications of too small patient subgroups, sev-
eral variables were grouped to maintain a sufficient number 
of patients in each subgroup. Tumor subtypes were merged 
into three main categories: ductal carcinoma, lobular car-
cinoma, and other tumor subtypes. For this reason, also the 
type of neoadjuvant therapy was reclassified into 4 catego-
ries: chemotherapy, hormonal therapy, other or combined 
therapy, and no therapy. The primary tumor (T), regional 
lymph nodes (N), and distant metastases (M) stage (TNM) 
was defined according to the eight edition of the TNM stag-
ing system [17]. In this staging system, a N1mi classifica-
tion can only exist in combination with T1. The N-stage of 
patients for whom a higher T-stage was recorded in com-
bination with this N1mi was assumed to be a N1-N-stage.
Potential cost savings of omitting multiple tests
Potential cost savings from avoiding unnecessary tests (i.e., 
with outcomes similar to the initial test) were calculated. 
Based on the total number of concordant test results in either 
ER/PR/HER2, or combinations of those, the number of tests 
that potentially could have been omitted was calculated. 
Costs for each test, or combinations of tests, were derived 
from the Dutch Healthcare Authority (NZa). The ER and 
PR status are generally tested by using an IHC. In the cal-
culation of the potential cost savings, it was assumed that 
the costs for testing both ER and PR on the same excerpt 
were equal to those of a single test for either ER or PR. If 
HER2 was additionally tested, additional costs of the HER2 
antibody were added to the costs of performing an IHC, 
whereas IHC in combination with either ER, PR, or both 
was assumed to be equally expensive to performing an IHC 
for HER2 singularly.
Results
Patient-level data derived from PALGA included 11,054 
patients with invasive breast cancer whom were diagnosed 
(i.e., had a biopsy) after January 12, 2016. Patients whom 
had either one excerpt record (n = 92; 0.66%) or more than 
two excerpt records (n = 2081; 15.00%) were excluded from 
further analysis. The final dataset used for further analyses 
consisted of 8,881 unique patients, whom all had one biopsy 
and one tumor resection record. An overview of all patient 
characteristics is provided in Table 1.
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Discordance
To calculate discordance, only those patients were selected 
for whom the ER, PR, or HER2 was determined on both 
biopsy and tumor resection material. For 1279 patients, 
either ER, PR, or HER2 was determined on both excerpts 
(14.40%). For those patients who only had 1 ER, PR, or 
HER2 determination, the majority of patients had their sta-
tus determined on resection material (ER n = 4343; 57.13%, 
PR n = 4363; 57.39%, HER2 n = 4772; 62.78%). Discord-
ance in each of the receptors for patients with ER, PR, and 
HER2 determined on both excerpts is shown in Table 2.
In a substantial number of patients (n = 590; 47.20%), the 
ER and PR receptors were both tested on biopsy and tumor 
resection material. Discordance in both receptors was found 
in a small number of patients (n = 7; 1.19%).
A substantial percentage of all patients for whom either 
the ER, PR, or HER2 status was determined on both biopsy 
and tumor resection material received no NAT (n = 1070; 
85.60%), which is slightly lower than the relative number of 
patients not receiving any NAT in the full dataset (n = 7858; 
88.48%). The percentage of patients having discordance in 
ER or PR test results is higher in patients receiving either 
neoadjuvant chemotherapy or hormonal therapy, as shown 
in Table 3.
Of those patients with discordance in both the ER and PR 
receptors (n = 7; 1.19%), 1 patient received chemotherapy, 
whereas all others received no neoadjuvant therapy.
Table 1  Summarized overview of clinically relevant patient characteristics
Category Sub-categories Total number of 
patients
Therapy
No NAT Chemotherapy Hormonal therapy Other therapy
Bloom Richardson 
grade
Unknown 618 (6.96%) 112 (18.12%) 437 (70.71%) 47 (7.61%) 22 (3.56%)
Grade I 2464 (27.74%) 2324 (94.32%) 105 (4.26%) 34 (1.38%) 1 (0.04%)
Grade II 4086 (46.01%) 3827 (93.66%) 205 (5.02%) 49 (1.2%) 5 (0.12%)
Grade III 1713 (19.29%) 1595 (93.11%) 105 (6.13%) 11 (0.64%) 2 (0.12%)
Response to therapy No response 7984 (89.9%) 7858 (98.42%) 86 (1.08%) 35 (0.44%) 5 (0.06%)
< 10% tumor remaining 232 (2.61%) 0 (0.00%) 216 (93.10%) 6 (2.59%) 10 (4.31%)
10–50% tumor remain-
ing
325 (3.66%) 0 (0.00%) 281 (86.46%) 36 (11.08%) 8 (2.46%)
> 50% tumor remaining 340 (3.83%) 0 (0.00%) 269 (79.12%) 64 (18.82%) 7 (2.06%)
TNM stage 0 506 (5.70%) 476 (94.07%) 25 (4.94%) 4 (0.79%) 1 (0.20%)
IA 688 (7.75%) 673 (97.82%) 13 (1.89%) 2 (0.29%) 0 (0.00%)
IB 4226 (47.58%) 3862 (91.39%) 317 (7.50%) 37 (0.88%) 10 (0.24%)
IIA 330 (3.72%) 299 (90.61%) 26 (7.88%) 3 (0.91%) 2 (0.61%)
IIB 1967 (22.15%) 1680 (85.41%) 229 (11.64%) 50 (2.54%) 8 (0.41%)
IIIA 739 (8.32%) 589 (79.70%) 119 (16.10%) 27 (3.65%) 4 (0.54%)











Tumor type Ductal 98 (1.10%) 78 (79.59%) 19 (19.39%) 1 (1.02%) 0 (0.00%)
Lobular 6999 (78.81%) 6166 (88.10%) 715 (10.22%) 91 (1.30%) 27 (0.39%)
Other 1212 (13.65%) 1067 (88.04%) 101 (8.33%) 41 (3.38%) 3 (0.25%)
Total 8881 (100%) 7858 (88.48%) 852 (9.59%) 141 (1.59%) 30 (0.34%)
Table 2  Discordance in test 
results between biopsy and 
tumor resection material
a The population size described shows the number of patients for whom each of the specific receptors was 
determined on both biopsy and tumor resection material




ER 684 (7.70%) 31 (4.53%) 20 (64.52%) 11 (35.48%)
PR 890 (10.02%) 135 (15.17%) 67 (49.63%) 68 (50.37%)
HER2 707 (7.96%) 6 (0.85%) 0 (0.00%) 6 (100%)
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Influence of tumor and patient characteristics 
on discordance
Logistic regression models for ER, PR, and HER2 discord-
ance separately were established using the stepwise algo-
rithm. For HER2 discordance, however, the model could not 
be established properly, as only a few patients had discord-
ance in this receptor (n = 6), and was therefore not further 
evaluated. In the remaining regression analyses (ER and 
PR), the TNM stages were merged into stage 0–1, stage 2, 
and stage 3. Patients with different types of NAT, i.e., other 
than chemotherapy, hormonal therapy, or no NAT, were 
excluded from this analysis (n = 30; 7.67%).
In the regression analysis modeling ER discordance, 
the stepwise algorithm indicated that including ER and PR 
biopsy classification, the BR grade, the response to therapy 
(if any), and the HER2 IHC result of the biopsy results in 
a model with the lowest AIC. For PR discordance, the best 
performing model contains the type of neoadjuvant therapy 
(if any), the ER and PR biopsy classification, the TNM 
stage, and the tumor type. The derived odds ratios from both 
models, 95% confidence intervals (CIs), standard errors, and 
the corresponding p values are shown in Table 4.
The outcomes of the logistic regression analyses, as 
shown in Table 4, show that the probability of discordance 
in the ER receptor is higher for patients with an ER-positive 
biopsy classification than for patients with an ER-negative 
biopsy classification (OR 3.629), whereas the probability 
of discordance in this ER receptor is lower for patients with 
a PR-positive biopsy classification compared to patients 
with a PR-negative biopsy classification (OR 0.132). The 
probability of discordance in the PR receptor is higher for 
patients with an ER-positive biopsy classification compared 
to patients with an ER-negative biopsy classification (OR 
6.031), whereas the probability of discordance in the PR 
receptor is lower for patients with a positive biopsy classi-
fication for HER2 derived by IHC compared to patients for 
whom no IHC was performed (OR 0.356).
When combining the different patient and tumor char-
acteristics, specific subgroups of patients can be deter-
mined with the highest and lowest probabilities of deriving 
discordant test results in either of the receptors. Patients with 
a BR Grade 3, a positive classification of ER on biopsy, and 
a positive classification of HER2 on biopsy derived by an 
amplified ISH who did receive neoadjuvant chemotherapy 
have the highest probability of an ER discordant test result 
(OR 1.274; p 56.01%), whereas patients with a BR Grade 2, 
a positive classification of PR on biopsy, and a negative clas-
sification of HER2 on biopsy derived by a not amplified ISH 
who did not receive any NAT at all have the lowest probabil-
ity of an ER discordant test result (OR ≤ 0.005; p = 0.02%). 
Patients with a lobular tumor type staged as TNM stage of 
2A or 2B, a positive classification of ER, a negative clas-
sification of PR, and no HER2 IHC performed on biopsy 
and who did receive neoadjuvant hormonal therapy have the 
highest probability of a PR discordant test result (OR 3.627; 
p = 78.39%), whereas patients with another tumor type than 
lobular or ductal, a TNM stage 3A, 3B, or 3C, a positive 
classification of PR on biopsy, and a positive classification 
of HER2 derived by a 3 + IHC result and who did not receive 
any form of NAT had the lowest probability of a PR discord-
ant test result (OR 0.006; p = 0.62%).
Potential cost savings
For the majority of patients in whom multiple tests were 
performed, the test results were concordant, ranging from 
84.83% in PR status to a concordance of 99.15% in the 
HER2 status. The cost of determining the ER and PR sta-
tus together is €151, whereas additionally determining the 
HER2 on an IHC is €100 more expensive. The cost of an 
ISH is approximately €408. Determining the ER, PR, and 
complete HER2 status (IHC and ISH) results in a cost of 
approximately €659.
Assuming (hypothetically) that test results can be per-
fectly predicted for patients with concordant test results, 
either one of the tests performed can potentially be omit-
ted. In Table 2, the total number of patients having discord-
ant test results was presented. However, as tests can be 
performed simultaneously, it was additionally calculated 
how many patients had concordant test results in all recep-
tor statuses (ER, PR, and HER2). A total of 325 full ER/
Table 3  Discordance in ER, PR 
or HER2 receptor status and 
neoadjuvant therapy
a Row sums of the subpopulations that were tested multiple times for each receptor do not add up to popula-
tion size as presented in column 2, Table 2. Some patients (range 2–5 for the different receptors) received 
another therapy than chemotherapy or hormonal therapy. None of these patients had discordant test results 
for any of the receptors
Chemotherapy Hormonal therapy No NAT
Population Discordant Population Discordant Population Discordant
ER 96 (11.27%) 9 (9.38%) 17 (12.06%) 1 (5.88%) 568 (7.23%) 21 (3.70%)
PR 110 (12.91%) 21 (19.09%) 30 (21.28%) 12 (40.00%) 745 (9.48%) 99 (13.29%)
HER2 51 (5.99%) 3 (5.88%) 9 (6.38%) 0 (0.00%) 645 (8.21%) 3 (0.47%)
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PR/HER2 tests can potentially be omitted, as all receptors 
were found to be concordant (approximately €214,000). In 
addition, also ER and PR are often tested simultaneously. 
A total of 179 tests can additionally be potentially omit-
ted, as 179 patients had a combined ER/PR test and con-
cordant test results for both receptors while not having had 
two HER2 determinations (approximately €27,000). The 
number of patients with double tests for ER, PR, or HER2 
singularly (double tests in only 1 receptor) was then calcu-
lated, resulting in additional cost savings of approximately 
€169,000. In total, potential cost savings can sum up to 
approximately €410,000 when concordance in test results 
can be perfectly predicted, and second tests can therefore 
safely be omitted. Determining the ER/PR/HER2 status 
on both biopsy and tumor resection material is currently 
already selectively performed (n = 1279; 14.40%). How-
ever, cost savings for this particular patient group (from 
2016 till 2018) may still result in yearly cost savings of 
approximately €205,000. Overall, these results indicate 
that an average cost saving of up to €320 per patient can 
potentially be reached.
Discussion
The majority of patients had two excerpt records in their 
pathology reports. These results are in accordance with what 
was expected for most breast cancer patients and in line 
with the Dutch breast cancer guideline, as usually a biopsy 
is done to confirm breast cancer after which the tumor is 
Table 4  Results of the logistic regression analyses per receptor
a The intercept reflects the probability of discordance for the total reference category of patients. For the prediction of ER discordance, these 
patients have an ER-negative but PR-positive biopsy classification, an unknown BR grade, had no ISH performed on the biopsy material, and did 
not receive any form of NAT
b Both tumor types appear to have a non-significant influence compared to a different type of tumor. This is due to recoding this variable. Ductal 
and lobular are significantly different from each other
ER discordance Odds ratio Std. error P value CI 2.5% CI 97.5%
Intercepta 0.050 2.382 0.001 0.008 0.254
ER biopsy classification (ref. biopsy 
negative, n = 463)
Positive (n = 463) 3.629 1.654 0.010 1.378 10.073
PR biopsy classification (ref. biopsy 
negative, n = 267)
Positive (n = 267) 0.132 1.709 0.000 0.043 0.361
BR grade (ref. unknown BR grade, 
n = 39)
Grade 1 (n = 121) 0.990 2.262 0.990 0.199 5.202
Grade 2 (n = 265) 0.191 2.412 0.060 0.031 1.074
Grade 3 (n = 198) 1.482 2.100 0.596 0.367 7.006
ISH biopsy result (ref. no ISH per-
formed, n = 420)
Amplified (n = 31) 1.399 2.013 0.631 0.293 4.939
Not Amplified (n = 172) 0.191 2.228 0.039 0.028 0.736
NAT (ref. no NAT, n = 518) Chemotherapy (n = 90) 3.355 1.695 0.022 1.141 9.245
Hormonal therapy (n = 15) 3.230 3.171 0.310 0.157 22.473
PR discordance Odds ratio Std. error P value CI 2.5% CI 97.5%
Intercept 0.036 1.874 0.000 0.009 0.113
ER biopsy classification (ref. biopsy 
negative, n = 142)
Positive (n = 673) 6.031 1.589 0.000 2.609 16.505
TNM Stadium (ref. stadium 0–1, 
n = 458)
TNM stadium 2 (n = 312) 1.910 1.250 0.004 1.236 2.965
TNM stadium 3 (n = 45) 0.973 1.622 0.955 0.353 2.396
NAT (ref. no NAT, n = 683) Chemotherapy (n = 104) 2.188 1.361 0.011 1.177 3.959
Hormonal therapy (n = 28) 4.088 1.531 0.001 1.741 9.381
PR biopsy classification (ref. biopsy 
negative, n = 340)
Positive (n = 475) 0.500 1.261 0.003 0.317 0.790
IHC biopsy result (ref. no IHC per-
formed, n = 131)
IHC 2+ (n = 101) 0.927 1.430 0.833 0.457 1.865
IHC 0 (n = 212) 0.479 1.390 0.025 0.250 0.913
IHC 1+ (n = 323) 0.560 1.349 0.053 0.313 1.015
IHC 3+ (n = 48) 0.356 1.833 0.089 0.094 1.065
Tumor  typeb (ref. different type, 
n = 73)
Ductal (n = 618) 1.237 1.585 0.644 0.537 3.370
Lobular (n = 124) 2.146 1.645 0.125 0.855 6.192
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resected in invasive breast cancer. In general, for most 
patients (n = 7631; 85.9%) the ER, PR, and HER2 status 
were, however, only tested once on either biopsy or tumor 
resection material. Discordance in the ER/PR/HER2 recep-
tor was shown to be limited, with percentages of patients 
with discordant test results in either one of the receptors 
ranging from 0.9 to 15.2%. When testing for both the ER and 
PR receptors, discordance in test results was also found to 
be very low (1.19%). The percentages of patients with dis-
cordant test results were substantially higher in patients who 
received any form of NAT (i.e., chemotherapy or hormonal 
therapy) compared to those patients who did not receive any 
form of NAT.
Two separate multivariable stepwise logistic regression 
analyses were performed to calculate the probability of 
deriving discordant test results for the ER and PR receptors 
as a function of patient and tumor characteristics that are 
available directly after the biopsy. Even though the num-
bers of patients having discordant test results in specific 
subgroups are relatively low, the data suggest that several 
of these variables significantly influence the probability of 
deriving a discordant test result. However, before predict-
ing discordance using such models, these should be vali-
dated, which is often complex or even impossible in datasets 
in which a minority of observations is used to predict the 
outcome. In this study, small percentages of patients had a 
discordant test result, especially for ER and even more for 
HER2, whereas this percentage was slightly higher for PR. 
Consequently, validating the model for PR discordance may 
be easier, given the larger number of expected discordant test 
results. Although potentially feasible and valid in predicting 
discordance, singly testing the PR receptor is clinically less 
relevant than single tests for the ER and PR receptors. There-
fore, such a model would not serve its initial clinical aim, 
which is of course predicting discordance in clinically mean-
ingful receptors. However, the regression analyses do have 
provided valuable insight into the combination of patient 
and tumor characteristics which appear to be influencing the 
probability of discordance. For example, the probability of 
discordance can even be less than 1% in specific subgroups 
of patients.
Based on the results of the logistic regression model and 
the low percentages of patients with discordant test results 
that were found in this study, performing multiple tests is 
probably unnecessary for the majority of patients. However, 
a number of significant risk factors for discordance were 
identified in this study, suggesting that testing twice is likely 
beneficial in very specific subgroups of patients. As a next 
step, discordance risks should be validated in future stud-
ies, focusing particularly on patients with high predicted 
discordance risks, to further tailor multiple ER/PR/HER2 
testing.
Potential cost savings of omitting tests can potentially 
sum up to approximately €205,000 yearly. However, prices 
used in this calculation are list prices, which are not always 
reflecting the actual money paid for each test. In addition, 
potential cost savings were based on the assumption that 
discordance can be perfectly predicted, whereas it is hard 
to make perfect predictions in practice. Furthermore, to be 
able to estimate full potential cost impact, treatment deci-
sions based on discordance in these test results and guideline 
adherence regarding the use of these tests should also be 
taken into account.
No adjuvant treatment decisions based on the discord-
ance in this study were taken into account. Future studies 
should focus on the impact of discordant results on future 
treatment decisions. In addition, no survival results could yet 
be derived for this cohort of patients as these patients were 
diagnosed after January 12, 2016. Consequently, the follow-
up period of this patient cohort is (yet) too short to draw 
firm conclusions regarding survival. Future studies should 
incorporate the impact on treatment decisions and associated 
survival outcomes in further predicting the probability of 
potential discordance. In addition, further treatment deci-
sions related to discordance should be taken into account. 
Especially when treatment decisions will not differ, even 
though test results are discordant, additional testing may be 
omitted.
Conclusions
Testing for ER/PR/HER2 on both tumor biopsy and tumor 
resection material is not performed in the majority of 
patients. The discordance in test results of the ER/PR/HER2 
status in patients with invasive breast cancer is limited. Of 
all three receptors, remarkably the PR receptor status is most 
frequently measured on both biopsy and tumor resection 
material and was subsequently found to be discordant most 
frequently. In addition, the probability of a discordant test 
result is generally low, but can, however, be significantly 
influenced by several patient and tumor characteristics.
Future research investigating either discordance, their 
corresponding predictive models, or its potential conse-
quences should also take further treatment decisions and 
treatment outcomes into account for each of the receptors.
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